Yuan Zhao

Yuan Zhao

Auto-generated profile, based on publicly available information

Yuan Zhao

The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine Shenzhen 518033 China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Open access
YMYicheng Mao
Yicheng Mao
Jiang WangJiang Wang
Jiang Wang
YZYuan Zhao
Yuan Zhao
YWYun Wu
Yun Wu
KKKwang Joo Kwak
Kwang Joo Kwak
NMNatarajan Muthusamy
Natarajan Muthusamy
We describe here the development and characterization of the physicochemical and pharmacokinetic properties of a novel liposomal formulation for FTY720 delivery, LP-FTY720. The mean diameter of LP-FTY720 was ~157 nm, and the FTY720 entrapment efficiency was ~85%. The liposomal formulation protected FTY720 from degradation in aqueous buffer and showed toxicity in CLL patient B cells comparable to that of free FTY720. Following intravenous injection in ICR mice, LP-FTY720 had an increased elimination phase half-life (~28 vs. ~19 hr) and decreased clearance (235 vs. 778 mL/h/kg) compared to the free drug. Antibodies against CD19, CD20 and CD37 were incorporated into LP-FTY720, which provided targeted delivery to CLL patient B cells and thus achieved higher killing efficacy. The novel liposomal carrier of FTY720 demonstrated improved pharmacokinetic properties, comparable activity, and a potential platform for targeted delivery to CLL by overcoming the limited application of free FTY720 to B malignancy treatment. This team reports on a novel liposomal formulation for FTY720 delivery, demonstrating improved pharmacokinetic properties, comparable activity, and a potential platform for targeted delivery to CLL using antibodies incorporated in the liposomes. The method expected to overcome the limited application of free FTY720 to B malignancy treatment.


9 October 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YZYuan Zhao
Yuan Zhao
JWJinru Wu
Jinru Wu
XLXiangbin Li
Xiangbin Li
QCQiugu Chen
Qiugu Chen
ZHZhiming Hong
Zhiming Hong
JCJianping Chen
Jianping Chen

22 May 2014 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Open access
YMYicheng Mao
Yicheng Mao
JWJiang Wang
Jiang Wang
YZYuan Zhao
Yuan Zhao
RYRibai Yan
Ribai Yan
HLHao Li
Hao Li
MPMitch A Phelps
Mitch A Phelps
OSU-2S is a novel anti-cancer and immune modulatory agent designed specifically to avert the immunosuppressive effects and related toxicities observed in clinical studies with its predecessor analog, FTY720. To characterize its preclinical pharmacokinetics, a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed and validated for the quantification of OSU-2S in mouse plasma. Ethyl acetate extraction of samples containing OSU-2S and the internal standard, Sph-17, was followed by separation with a 6 min gradient (water/0.1% formic acid and methanol/0.1% formic acid) on a reverse-phase C18 column at room temperature. Selected reaction monitoring was used for detection on a triple quadrupole mass spectrometer with positive ionization. The assay was linear over the concentration range 3-3000 ng/mL with accuracy ranging from 103 to 111%, and both within- and between-run precision (CV%) ≤11%. All stability samples were within ±15% of nominal values, and replicates were within 15% CV. The assay was successfully applied to a mouse pharmacokinetic study of OSU-2S with intravenous and intraperitoneal administration. OSU-2S non-compartmental pharmacokinetic parameters, area under the concentration–time curve, clearance, and elimination half-life were estimated at 1522 h μg/L, 3.06 L/h/kg and 15.6 h, respectively, for intravenous injection. Systemic availability after intraperitoneal injection was approximately 46%. These data demonstrate the OSU-2S compound displays acceptable pharmacokinetic properties for further in vivo pharmacologic evaluation, which can be facilitated by the validated LC–MS/MS assay.

11 October 2024 in Biomedical Chromatography
Verified
Journal Article
Closed access
YZYuan Zhao
Yuan Zhao
JWJinru Wu
Jinru Wu
XLXiangbin Li
Xiangbin Li
LZLin Zheng
Lin Zheng
QCQiugu Chen
Qiugu Chen
JCJianping Chen
Jianping Chen